Co-Authors
This is a "connection" page, showing publications co-authored by Shibo Jiang and Lanying Du.
Connection Strength
19.702
-
Neutralizing antibodies for the treatment of COVID-19. Nat Biomed Eng. 2020 12; 4(12):1134-1139.
Score: 0.916
-
Therapeutic antibodies and fusion inhibitors targeting the spike protein of SARS-CoV-2. Expert Opin Ther Targets. 2021 06; 25(6):415-421.
Score: 0.903
-
Effect of Low-Pathogenic Human Coronavirus-Specific Antibodies on SARS-CoV-2. Trends Immunol. 2020 10; 41(10):853-854.
Score: 0.897
-
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses: (Trends in Immunology 41, 355-359; 2020). Trends Immunol. 2020 06; 41(6):545.
Score: 0.879
-
Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020 05; 41(5):355-359.
Score: 0.875
-
The latest advancements in Zika virus vaccine development. Expert Rev Vaccines. 2017 10; 16(10):951-954.
Score: 0.728
-
MERS-CoV spike protein: a key target for antivirals. Expert Opin Ther Targets. 2017 Feb; 21(2):131-143.
Score: 0.697
-
Vaccines for the prevention against the threat of MERS-CoV. Expert Rev Vaccines. 2016 09; 15(9):1123-34.
Score: 0.664
-
Middle East respiratory syndrome: current status and future prospects for vaccine development. Expert Opin Biol Ther. 2015; 15(11):1647-51.
Score: 0.640
-
A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines. PLoS One. 2013; 8(12):e81587.
Score: 0.564
-
Identification of a receptor-binding domain in the S protein of the novel human coronavirus Middle East respiratory syndrome coronavirus as an essential target for vaccine development. J Virol. 2013 Sep; 87(17):9939-42.
Score: 0.548
-
Antibodies induced by receptor-binding domain in spike protein of SARS-CoV do not cross-neutralize the novel human coronavirus hCoV-EMC. J Infect. 2013 Oct; 67(4):348-50.
Score: 0.543
-
Receptor-binding domains of spike proteins of emerging or re-emerging viruses as targets for development of antiviral vaccines. Emerg Microbes Infect. 2012 Aug; 1(8):e13.
Score: 0.515
-
Protocol for recombinant RBD-based SARS vaccines: protein preparation, animal vaccination and neutralization detection. J Vis Exp. 2011 May 02; (51).
Score: 0.471
-
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity. Viral Immunol. 2010 Apr; 23(2):211-9.
Score: 0.437
-
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity. Virology. 2009 Oct 10; 393(1):144-50.
Score: 0.419
-
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells. Biochem Biophys Res Commun. 2009 Jul 10; 384(4):486-90.
Score: 0.411
-
The spike protein of SARS-CoV--a target for vaccine and therapeutic development. Nat Rev Microbiol. 2009 Mar; 7(3):226-36.
Score: 0.404
-
Learning from the past: development of safe and effective COVID-19 vaccines. Nat Rev Microbiol. 2021 03; 19(3):211-219.
Score: 0.227
-
A novel receptor-binding domain (RBD)-based mRNA vaccine against SARS-CoV-2. Cell Res. 2020 10; 30(10):932-935.
Score: 0.224
-
Identification of SARS-CoV RBD-targeting monoclonal antibodies with cross-reactive or neutralizing activity against SARS-CoV-2. Antiviral Res. 2020 07; 179:104820.
Score: 0.220
-
From SARS-CoV to SARS-CoV-2: safety and broad-spectrum are important for coronavirus vaccine development. Microbes Infect. 2020 Jul - Aug; 22(6-7):245-253.
Score: 0.220
-
Current development of COVID-19 diagnostics, vaccines and therapeutics. Microbes Infect. 2020 Jul - Aug; 22(6-7):231-235.
Score: 0.220
-
Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cell Mol Immunol. 2020 06; 17(6):613-620.
Score: 0.218
-
Subunit Vaccines Against Emerging Pathogenic Human Coronaviruses. Front Microbiol. 2020; 11:298.
Score: 0.217
-
Recent advances in the detection of respiratory virus infection in humans. J Med Virol. 2020 04; 92(4):408-417.
Score: 0.216
-
Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect. 2020 03; 22(2):74-79.
Score: 0.216
-
An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies. Emerg Microbes Infect. 2020; 9(1):275-277.
Score: 0.216
-
A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life. Molecules. 2019 Mar 21; 24(6).
Score: 0.204
-
Transfusion-Transmitted Zika Virus Infection in Pregnant Mice Leads to Broad Tissue Tropism With Severe Placental Damage and Fetal Demise. Front Microbiol. 2019; 10:29.
Score: 0.201
-
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain. Viruses. 2019 01 14; 11(1).
Score: 0.201
-
Prospects for a MERS-CoV spike vaccine. Expert Rev Vaccines. 2018 08; 17(8):677-686.
Score: 0.195
-
Critical neutralizing fragment of Zika virus EDIII elicits cross-neutralization and protection against divergent Zika viruses. Emerg Microbes Infect. 2018 Jan 24; 7(1):7.
Score: 0.188
-
HIV-1 gp41-targeting fusion inhibitory peptides enhance the gp120-targeting protein-mediated inactivation of HIV-1 virions. Emerg Microbes Infect. 2017 Jun 21; 6(6):e59.
Score: 0.180
-
Anti-HIV antibody and drug combinations exhibit synergistic activity against drug-resistant HIV-1 strains. J Infect. 2017 07; 75(1):68-71.
Score: 0.177
-
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol. 2017 Jan 01; 91(1).
Score: 0.174
-
Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines. Nat Commun. 2016 11 22; 7:13473.
Score: 0.173
-
Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Sci Rep. 2015 Aug 19; 5:13028.
Score: 0.159
-
Protective Effect of Intranasal Regimens Containing Peptidic Middle East Respiratory Syndrome Coronavirus Fusion Inhibitor Against MERS-CoV Infection. J Infect Dis. 2015 Dec 15; 212(12):1894-903.
Score: 0.157
-
Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus. Cell Mol Immunol. 2016 Mar; 13(2):180-90.
Score: 0.153
-
Receptor-binding domain-based subunit vaccines against MERS-CoV. Virus Res. 2015 Apr 16; 202:151-9.
Score: 0.151
-
Testing of Middle East respiratory syndrome coronavirus replication inhibitors for the ability to block viral entry. Antimicrob Agents Chemother. 2015 Jan; 59(1):742-4.
Score: 0.150
-
Middle East respiratory syndrome coronavirus (MERS-CoV) entry inhibitors targeting spike protein. Virus Res. 2014 Dec 19; 194:200-10.
Score: 0.150
-
Searching for an ideal vaccine candidate among different MERS coronavirus receptor-binding fragments--the importance of immunofocusing in subunit vaccine design. Vaccine. 2014 Oct 21; 32(46):6170-6176.
Score: 0.149
-
Calling for rapid development of a safe and effective MERS vaccine. Microbes Infect. 2014 Jul; 16(7):529-31.
Score: 0.146
-
Current advancements and potential strategies in the development of MERS-CoV vaccines. Expert Rev Vaccines. 2014 Jun; 13(6):761-74.
Score: 0.145
-
A conformation-dependent neutralizing monoclonal antibody specifically targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. J Virol. 2014 Jun; 88(12):7045-53.
Score: 0.144
-
Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014 Apr 11; 32(18):2100-8.
Score: 0.143
-
Structure-based discovery of Middle East respiratory syndrome coronavirus fusion inhibitor. Nat Commun. 2014; 5:3067.
Score: 0.142
-
Yeast-expressed recombinant protein of the receptor-binding domain in SARS-CoV spike protein with deglycosylated forms as a SARS vaccine candidate. Hum Vaccin Immunother. 2014; 10(3):648-58.
Score: 0.142
-
Receptor-binding domain as a target for developing SARS vaccines. J Thorac Dis. 2013 Aug; 5 Suppl 2:S142-8.
Score: 0.138
-
Middle East respiratory syndrome coronavirus (MERS-CoV): challenges in identifying its source and controlling its spread. Microbes Infect. 2013 Jul-Aug; 15(8-9):625-9.
Score: 0.137
-
Putative conformations of the receptor-binding domain in S protein of hCoV-EMC in complex with its receptor dipeptidyl peptidase-4. J Infect. 2013 Aug; 67(2):156-8.
Score: 0.135
-
A predicted receptor-binding and critical neutralizing domain in S protein of the novel human coronavirus HCoV-EMC. J Infect. 2013 May; 66(5):464-6.
Score: 0.132
-
Roadmap to developing a recombinant coronavirus S protein receptor-binding domain vaccine for severe acute respiratory syndrome. Expert Rev Vaccines. 2012 Dec; 11(12):1405-13.
Score: 0.132
-
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection. Vaccine. 2008 Mar 20; 26(13):1644-51.
Score: 0.094
-
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. J Immunol. 2008 Jan 15; 180(2):948-56.
Score: 0.094
-
Development of subunit vaccines against severe acute respiratory syndrome. Drugs Today (Barc). 2008 Jan; 44(1):63-73.
Score: 0.094
-
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity. Biochem Biophys Res Commun. 2007 Jul 20; 359(1):174-9.
Score: 0.090
-
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model. Vaccine. 2007 Apr 12; 25(15):2832-8.
Score: 0.086
-
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines. Virology. 2006 Sep 15; 353(1):6-16.
Score: 0.084
-
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine. Vaccine. 2006 Jun 29; 24(26):5498-508.
Score: 0.083
-
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement. Vaccine. 2020 11 03; 38(47):7533-7541.
Score: 0.057
-
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res. 2020 Apr; 30(4):343-355.
Score: 0.055
-
A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. 2019 04; 5(4):eaav4580.
Score: 0.051
-
A Novel Nanobody Targeting Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Receptor-Binding Domain Has Potent Cross-Neutralizing Activity and Protective Efficacy against MERS-CoV. J Virol. 2018 09 15; 92(18).
Score: 0.049
-
Treatment of Paraquat-Induced Lung Injury With an Anti-C5a Antibody: Potential Clinical Application. Crit Care Med. 2018 05; 46(5):e419-e425.
Score: 0.048
-
Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV. Emerg Microbes Infect. 2018 Apr 24; 7(1):77.
Score: 0.048
-
Engineering a stable CHO cell line for the expression of a MERS-coronavirus vaccine antigen. Vaccine. 2018 03 27; 36(14):1853-1862.
Score: 0.047
-
Cross-neutralization of SARS coronavirus-specific antibodies against bat SARS-like coronaviruses. Sci China Life Sci. 2017 12; 60(12):1399-1402.
Score: 0.046
-
Neutralization of Zika virus by germline-like human monoclonal antibodies targeting cryptic epitopes on envelope domain III. Emerg Microbes Infect. 2017 Oct 11; 6(10):e89.
Score: 0.046
-
Highly conserved M2e and hemagglutinin epitope-based recombinant proteins induce protection against influenza virus infection. Microbes Infect. 2017 12; 19(12):641-647.
Score: 0.046
-
A peptide-based viral inactivator inhibits Zika virus infection in pregnant mice and fetuses. Nat Commun. 2017 07 25; 8:15672.
Score: 0.045
-
Receptor-binding domain of MERS-CoV with optimal immunogen dosage and immunization interval protects human transgenic mice from MERS-CoV infection. Hum Vaccin Immunother. 2017 07 03; 13(7):1615-1624.
Score: 0.044
-
A recombinant receptor-binding domain of MERS-CoV in trimeric form protects human dipeptidyl peptidase 4 (hDPP4) transgenic mice from MERS-CoV infection. Virology. 2016 12; 499:375-382.
Score: 0.043
-
Cell Entry of Porcine Epidemic Diarrhea Coronavirus Is Activated by Lysosomal Proteases. J Biol Chem. 2016 Nov 18; 291(47):24779-24786.
Score: 0.043
-
Multi-Organ Damage in Human Dipeptidyl Peptidase 4 Transgenic Mice Infected with Middle East Respiratory Syndrome-Coronavirus. PLoS One. 2015; 10(12):e0145561.
Score: 0.041
-
Characterization and Demonstration of the Value of a Lethal Mouse Model of Middle East Respiratory Syndrome Coronavirus Infection and Disease. J Virol. 2016 01 01; 90(1):57-67.
Score: 0.040
-
Junctional and allele-specific residues are critical for MERS-CoV neutralization by an exceptionally potent germline-like antibody. Nat Commun. 2015 Sep 15; 6:8223.
Score: 0.040
-
Two Mutations Were Critical for Bat-to-Human Transmission of Middle East Respiratory Syndrome Coronavirus. J Virol. 2015 Sep; 89(17):9119-23.
Score: 0.039
-
Receptor usage and cell entry of porcine epidemic diarrhea coronavirus. J Virol. 2015 Jun; 89(11):6121-5.
Score: 0.039
-
Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus. Hum Vaccin Immunother. 2015; 11(5):1244-50.
Score: 0.038
-
Receptor usage and cell entry of bat coronavirus HKU4 provide insight into bat-to-human transmission of MERS coronavirus. Proc Natl Acad Sci U S A. 2014 Aug 26; 111(34):12516-21.
Score: 0.037
-
Exceptionally potent neutralization of Middle East respiratory syndrome coronavirus by human monoclonal antibodies. J Virol. 2014 Jul; 88(14):7796-805.
Score: 0.036
-
A safe and convenient pseudovirus-based inhibition assay to detect neutralizing antibodies and screen for viral entry inhibitors against the novel human coronavirus MERS-CoV. Virol J. 2013 Aug 26; 10:266.
Score: 0.035
-
The adjuvanticity of an O. volvulus-derived rOv-ASP-1 protein in mice using sequential vaccinations and in non-human primates. PLoS One. 2012; 7(5):e37019.
Score: 0.032
-
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients. Virol J. 2010 Nov 04; 7:299.
Score: 0.028